

DATE: April 15, 2022
TO: All Well Sense Health Plan Providers
FROM: Well Sense Health Plan
SUBJECT: **Pharmacotherapy for Opioid Use Disorder (POD)**
PRODUCT: *Medicaid* *Medicare Advantage*

Pharmacotherapy for Opioid Use Disorder (POD)

General Information

Well Sense Health Plan and Beacon Health Options are committed to promoting a high quality of care for the Well Sense membership. To evaluate performance on important care and service measures, we use the Healthcare Effectiveness Data and Information Set (HEDIS[®])¹ tool.

Encouraging the use of pharmacotherapy for patients with Opioid Use Disorder (OUD) is a continuing area of focus in 2022, as this treatment option is critical in preventing relapse and overdose. The HEDIS measure **Pharmacotherapy for Opioid Use Disorder (POD)** assesses the percentage of OUD treatment events among patients age 16 and older who remain adherent to their OUD treatment for at least 180 days (six months).

[This HEDIS Provider Tip Sheet](#) includes information related to the POD measure and other OUD treatment resources. Beacon's website also provides additional resources: [Achieve Solutions | Substance Use Disorders Treatment and Recovery](#).

¹ HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA).